ARTICLE | Clinical News
ABO-102: Interim Ph I/II data
December 1, 2016 11:38 AM UTC
Interim data from 3 patients with MPS IIIA in an open-label, U.S. Phase I/II trial showed that a single IV injection of 5x1012 vg/kg ABO-102 was well tolerated with no treatment-related serious advers...
BCIQ Company Profiles
BCIQ Target Profiles